Press Releases

Press Releases

Impella ECP Pivotal Study Demonstrates Safety, Efficacy for Use in High-Risk PCI Blog Image

Impella ECP Pivotal Study Demonstrates Safety, Efficacy for Use in High-Risk PCI

Read More
New Data at TCT 2024 Expands on Recently Published New England Journal of Medicine Randomized Controlled Trial Demonstrating a Survival Benefit from Impella® Heart Pumps Blog Image

New Data at TCT 2024 Expands on Recently Published New England Journal of Medicine Randomized Controlled Trial Demonstrating a Survival Benefit from Impella® Heart Pumps

Read More
Abiomed Celebrates 25 Years of Heart Recovery with Impella® Blog Image

Abiomed Celebrates 25 Years of Heart Recovery with Impella®

Learn More
Randomized Controlled Trial Confirms Impella CP® Improves Survival in Heart Attack with Cardiogenic Shock Blog Image

Randomized Controlled Trial Confirms Impella CP® Improves Survival in Heart Attack with Cardiogenic Shock

Learn More
Analysis Showcases Potential for More Complete Revascularizations with Impella Compared to IABP during HRPCI Blog Image

Analysis Showcases Potential for More Complete Revascularizations with Impella Compared to IABP during HRPCI

Read More
Johnson & Johnson Completes Acquisition of Abiomed Blog Image

Johnson & Johnson Completes Acquisition of Abiomed

Learn More
FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical Trial Blog Image

FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical Trial

Read More
First Patients in the World Treated with Impella RP Flex with SmartAssist Blog Image

First Patients in the World Treated with Impella RP Flex with SmartAssist

Read More
Johnson & Johnson to Acquire Abiomed Blog Image

Johnson & Johnson to Acquire Abiomed

Learn More
Abiomed Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure Blog Image

Abiomed Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure

Read More
Yale University Study Demonstrates Significant Survival Benefit in High-Risk PCI with Impella Support Blog Image

Yale University Study Demonstrates Significant Survival Benefit in High-Risk PCI with Impella Support

Read More
Multi-Center, Multi-Society Study of Impella®-Supported Patients with Cardiogenic Shock due to Myocarditis in Japan Achieves 30-day Survival of 77% Blog Image

Multi-Center, Multi-Society Study of Impella®-Supported Patients with Cardiogenic Shock due to Myocarditis in Japan Achieves 30-day Survival of 77%

Read More
Large, Multi-Center, Multi-Society Study of Impella-supported Patients Finds 30-day AMI Cardiogenic Shock Survival of 81% Blog Image

Large, Multi-Center, Multi-Society Study of Impella-supported Patients Finds 30-day AMI Cardiogenic Shock Survival of 81%

Read More
Unloading with Impella® for 30 Minutes Before PCI Associated with Reduced Infarct Size in STEMI Patients Blog Image

Unloading with Impella® for 30 Minutes Before PCI Associated with Reduced Infarct Size in STEMI Patients

Read More
Restore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI Patients Supported by Impella Blog Image

Restore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI Patients Supported by Impella

Read More

NPS-2558

The Protected PCI community
is now on HeartRecovery.com

Providing education and training to help health care professionals
recover hearts, oxygenate the body and save lives.
Explore Now